Skip to content{"success":true,"data":{"id":"twse-mops-2lyy7w","title":"公告本公司開發中新藥BRM424治療神經營養性角膜炎 第II期人體臨床試驗初步結果(Topline Results)。","summary":"1.事實發生日:115/09/19 2.研發新藥名稱或代號:BRM424 3.用途:BRM424用於治療神經營養性角膜炎(Neurotrophic Keratitis, NK) 臨床試驗資訊網址： https://clinicaltrials.gov/study/NCT05927428?term=BRM424&rank=1 4.預計進行之所有研發階段:執行第二期臨床試驗及接續之臨床試驗 5.目前進行中之研發階段(請說明目前之研發階段係屬提出申請/通過核准/ 不通過核准，若未通過者，請說明公司所面臨之風險及因應措施； 另請說明未來經營方向及已投入累積研發費用): (1)提出申請/通過核准/不通過核准/各期人體臨床試驗(含期中分析)結果/ 發生其他影響新藥研發之重大事件： 在本項 Open-label 二期臨床試…","canonicalUrl":"https://mops.twse.com.tw/mops/web/t05st01?TYPEK=all&co_id=6885&encodeURIComponent=1&firstin=1&inpuType=co_id&off=1&step=1&year=115&spoke_date=20260921&spoke_time=031151","sourceName":"TWSE Market Observation Post System","sourceUrl":"https://mops.twse.com.tw/mops/web/t05st01","publishedAt":"2026-09-20T19:11:51.000Z","updatedAt":null,"language":"zh-TW","timeZone":"Asia/Taipei","region":"taiwan","country":"TW","market":"Taiwan","topics":["company-announcement","taiwan"],"relatedAssets":["6885"],"importance":"normal","image":null,"imageRights":null,"contentType":"company-announcement","disclosure":"Official company announcement from 全福生技; use the filtered MOPS search page to verify the complete filing.","provenance":{"sourceId":"twse-mops","sourceType":"exchange","official":true,"verification":"PRIMARY_SOURCE_METADATA","fetchedAt":"2026-09-22T17:33:20.098Z","stale":true,"archived":true,"classificationMethod":"RULE_BASED"}},"meta":{"generatedAt":"2026-09-22T17:38:31.251Z","providers":[{"id":"jiguang-news-archive","name":"Jiguang Finance source archive","kind":"news","status":"degraded","itemCount":1,"cache":"STALE","fetchedAt":"2026-09-22T17:33:20.098Z","sourceUrl":"https://jiguang.uk/sources.html","message":"Archived publisher metadata; original publication and fetch times retained. Archive availability is not source freshness."}],"stale":true,"apiVersion":"v2"},"error":null}